Welcome to the all-new Vetlearn

  • Vetlearn is becoming part of NAVC VetFolio.
    Starting in January 2015, Compendium and
    Veterinary Technician articles will be available on
    NAVC VetFolio. VetFolio subscribers will have
    access to not only the journals, but also:
  • Over 500 hours of CE
  • Community forums to discuss tough cases
    and networking with your peers
  • Three years of select NAVC Conference
  • Free webinars for the entire healthcare team

To access Vetlearn, you must first sign in or register.


  Sign up now for:
Become a Member

Compendium February 2007 (Vol 29, No 2)

Parenteral Nutrition: Formulation, Monitoring, and Complications

by Elizabeth Thomovsky, DVM, MS, DACVECC, Robert Backus, DVM, PhD, DACVN, Alisa Reniker, DVM, DACVECC, Fred Mann, DVM, MS, DACVS, DACVECC, John Dodam, DVM, MS, PhD, DACVA

    CETEST This course is approved for 2.0 CE credits

    Start Test


    Because decreased caloric and nutrient intake can complicate the course of both mild and serious illness, parenteral nutrition (PN) is an important feeding modality for patients unable to receive adequate enteral nutrition. Although the effectiveness of PN has not been proven in animals, human studies have shown that using PN in appropriately selected cases can improve clinical outcome, reduce hospitalization time, and even reduce the overall cost of patient care. PN formulations for animals are readily available through pharmacies.  This article provides practitioners with basic information on calculating and using PN in patients. Information is also provided on monitoring patients receiving PN as well as ways to identify and overcome common complications in animals receiving PN.

    Parenteral nutrition (PN) involves intravenous administration of nutrients to patients that require nutritional support and are anorectic despite correction of dehydration and other metabolic derangements. PN solutions are usually mixtures of dextrose solutions, lipid emulsions, and amino acid solutions that variably contain electrolytes, vitamins, and mineral supplements (see the companion article). When dextrose, lipids, and amino acids are used together in a PN formulation, the resulting mixture is called a three-in-one solution or total nutrient admixture. Three-in-one solutions are easy to administer; provide a patient's short-term amino acid, glucose, and energy needs in one solution; and are well tolerated by patients.1 Dextrose and amino acid solutions-without lipids-are given to patients as well. The use of these solutions can help avoid negative side effects of lipid administration. Dextrose and amino acid solutions do not need to be replaced on a daily basis as with lipid-containing admixtures but, because they contain fewer kilocalories per milliliter, require substantially greater volumes of delivery to meet caloric needs (see the companion article for the advantages and possible drawbacks of lipid supplementation).

    Published opinions differ on the appropriate estimate of nutrient requirements for a patient. For the purposes of the following discussion, we will describe the formulation method used by the University of Missouri-Columbia Veterinary Teaching Hospital and several other veterinary colleges. The formulation is based on descriptions by Remillard and Thatcher2 and Lippert and Armstrong3 and is similar to other methods described in the veterinary literature.4-6 However, re­search is ongoing in the field of veterinary nutrition, and the future may hold alterations to this formulation.

    Total Parenteral Nutrition Formulation

    To calculate total parenteral nutrition (TPN) rates, see Tables 1 and  2 .

    Step 1: Calculate the Basal Energy Requirement

    The basal energy requirement (BER) represents the energy requirement of an animal maintained under conditions involving the least energy expenditure for sustaining life:

    BER (kcal/day) = (30 x Body weight in kg [BWkg]) + 70

    (for patients weighing 2-45 kg)

    BER (kcal/day) = 70 (BWkg)0.75

    (for patients weighing <2 and >45 kg)

    BER is determined under experimental conditions when an animal is in a post-nutrient-absorptive state, not engaged in voluntary activity, and kept in a thermoneutral environment. BER is typically used as an approximation of a patient's resting energy requirement (RER), which is an animal's energy expenditure at rest under conditions less restricted than those used in measuring BER.2 BER and RER are often used interchangeably in the literature describing energy requirement estimation. For the body weight range indicated, the first BER equation is a useful linear interpolation of the second equation, which is commonly known as the Kleiber-Brody equation.

    A recent publication indicated that neither equation is a perfect estimation of BER for individual animals; the equations better represent the energy needs of populations of animals.7 Nonetheless, they are commonly used as a starting point for BER estimation. Some sources propose using the following equation for feline energy requirements8:

    BER = 40 x BWkg

    Proponents of this equation argue that for "typical" adult cats weighing 4.4 to 13.2 lb (2 to 6 kg), the total calculated caloric intake is too great when (30 x BWkg) + 70 is used to estimate BER and, by extension, patients are being nutritionally oversupplemented.

    Step 2: Determine the Total Energy Requirement

    The total energy requirement (TER) is also called the illness energy requirement (IER).

    TER = BER x Illness factor2

    Traditionally, illness factors range from 1.0 to 2.0. In the current system at the University of Missouri-Columbia, a burn patient would be assigned an illness factor of 2.0 to provide for increased losses of protein and fluid through cutaneous wounds. A patient with a hypermetabolic condition, such as sepsis, would have an illness factor of 1.7, whereas a patient without severe trauma or body protein losses would require only the BER and thus an illness factor of 1.0.

    These factors were initially derived from research in humans during the late 1970s and 1980s. The factors have been reported and repeated in the veterinary literature without direct verification of their use in animals and, therefore, may not be valid in animals.2

    The validity of multiplying the BER by an illness factor has recently been questioned.8,9 Human studies9,10 have shown that during periods of illness or after trauma, the body naturally transitions to a catabolic state. Insulin resistance occurs, and transient hyperglycemia may result. In this state, regardless of the amount of dextrose infused, the body cannot make full use of it. This brings into question the formerly ac­cepted idea that supplying large amounts of dextrose to stressed patients to meet their energy needs is appropriate in all cases.

    More recent human studies9,10 have also shown that increasing protein intake (as amino acids in PN) above the patient's basal metabolic needs does not effectively counter protein catabolism during periods of stress or illness. Amino acids that are unused for body protein needs are instead used to generate energy, resulting in proportionally increased metabolic urea and ammonia production.

    Therefore, the practice of multiplying the BER by an illness factor to supply greater amounts of energy as protein (in the form of amino acids), dextrose, and lipids may not benefit a patient and may actually be detrimental. There is agreement within the human literature that during stress and illness, a human's energy requirements do not increase more than 1.2 x BER.9 Thus the current movement in veterinary medicine is away from using illness factors in energy requirement calculations for all but a few select patients. Limiting the use of illness factors to specific cases can help avoid patient oversupplementation, which can lead to hyperglycemia, liver dysfunction, or unwanted metabolic acid and ammonia production.8 Most commonly, PN solutions are given at gradually increasing rates to meet the BER, and rate adjustments are made according to patient response as assessed during monitoring (see the Patient Monitoring section).

    Step 3: Determine the Protein Requirement

    As already discussed in this article and in the companion article, parenterally administered amino acids are used to replace amino acids lost in protein turnover and other biochemical pathways.2,3 It should be recognized that during both the fed and food-deprived states, amino acid catabolism is always occurring, albeit at different rates. Hence, regardless of whether protein requirements are met by amino acids given in PN admixtures, catabolism of amino acids always makes some contribution to body energy needs (see box).

    Although energy production from amino acid catabolism is well recognized, many parenteral formulations currently used in veterinary medicine (including the present formulation) do not account for energy derived from the provided amino acids. Such formulations are prepared so that the animal's energy requirement is completely supplied as dextrose and lipids. This is done to address the concern that most supplemented amino acids will be converted into energy via gluconeogenesis rather than used for protein synthesis and other anabolic processes if insufficient energy is supplied to the patient from other sources.2 Also, excessive amino acid supplementation may lead to the excretion of nitrogenous wastes, such as urea, which uses the energy derived from the supplemented dextrose and lipids.2

    For optimal use of parenteral amino acids in anabolic processes, it is believed that amino acids should be given in a certain proportion with energy. Therefore, the protein requirement (in amino acids) is determined per 100 kcal of TER in dogs.2 Because variation in body weight among adult cats is considerably less than that among adult dogs, the optimal protein:energy ratio in cats is suitably expressed as a ratio of grams of protein per kilogram of body weight.

    A 2001 study11 was conducted to determine the protein requirements of parenterally fed normal dogs using nitrogen balance methodology. It examined the presently used 4 g/kg/day estimation of canine protein requirements, which originated from a 1968 publication reporting research on PN in adult beagles.12 The recent work11 indicates that 2.3 g/kg/day is the intravenous amino acid requirement for clinically normal dogs fed their maintenance energy requirements (i.e., roughly equivalent to 2 x BER). At this time, it is unclear whether this amount of protein can be used in diseased dogs when supplying only BER, but it is possible that the protein requirement for dogs may be significantly less than the 4 to 6 g/kg/day traditionally used as the daily protein requirement.

    A study13 evaluating the effects of dietary protein restriction and amino acid deficiency on protein metabolism in dogs fed enterally concluded that a healthy dog's typical daily nitrogen requirement is 0.41 to 0.55 g/(kg0.75). A recent study14 conducted on healthy adult cats fed enterally concluded that they require 2.7 g/kg/day of crude protein to meet their needs. Both studies suggest that actual protein and amino acid requirements may be lower than current recommendations in cats and dogs. However, because both of these studies involved enteral provision of nutrients, it is difficult to know the relevance of these findings to PN formulation. In addition, these were healthy animals, and a direct correlation to systemically ill pets cannot be inferred.

    Step 4: Determine the Volume of Nutrient Solutions Required

    Dextrose Solution

    The dextrose solution most often used in TPN admixtures is 50% (500 mg/ml) dextrose and contains 1.7 kcal/ml. Patients typically receive 40% to 60% of their energy requirements from dextrose. If hyperglycemia or insulin resistance is an anticipated complication of PN, it may be better to provide closer to 40% of the energy requirements as dextrose. The remaining requirement for energy must be supplied through the lipid portion of the PN solution. To deliver 60% of a patient's energy (i.e., TER) from dextrose, the volume of solution can be calculated using the following equation:

    TER x 0.60 = ___ kcal/day of dextrose ÷ 1.7 kcal/ml = ___ ml of 50% dextrose per day

    Lipid Emulsion

    The lipid most commonly used in TPN admixtures is a 20% (200 mg/ml) vegetable oil emulsion containing 2 kcal/ml. Ten percent and 30% lipid emulsions are used in special cases. Patients typically receive 40% to 60% of their energy requirement as lipid. For 40% of the energy requirement (i.e., TER), calculate the volume of 20% lipid emulsion using the following equation:

    TER x 0.40 = ___ kcal/day of lipids ÷ 2 kcal/ml = ___ ml of 20% lipid solution per day

    Amino Acid Solution

    As with dextrose solutions and lipid emulsions, amino acid solutions are available in a variety of concentrations. The most commonly used solution is 8.5% (85 mg/ml) amino acids available with and without electrolytes. With the use of an 8.5% solution, the following equation can be used to calculate the volume of amino acid solution:

    _____ g protein/day ÷ 85 mg/ml x 1,000 mg/g = ______ ml/day

    Step 5: Determine the Total Volume of Total Parenteral Nutrition Solution

    (___ ml of dextrose + ___ ml of lipids + ___ ml of amino acids) ÷ 24 hr = ___ ml/hr

    First day: Typically administer one-third of this rate

    Second day: Typically administer two-thirds of this rate

    Third day: Typically administer at the full calculated daily rate

    Most patients are gradually introduced to TPN to avoid rebound hyperglycemia and other electrolyte abnormalities from the sudden infusion of large concentrations of dextrose (Figure 1; also, see the Patient Monitoring section). The patient may also require additional intravenous crystalloid fluids through another intravenous port to meet daily maintenance fluid and electrolyte requirements. In patients with severe electrolyte disturbances (e.g., diabetic ketoacidosis), the use of amino acid formulations without electrolytes may simplify case management. In such cases, electrolyte-containing solutions can be administered through a separate intravenous catheter to allow more controlled titration and provision for electrolyte deficits.

    Step 6: Determine the Daily Vitamin Requirements

    If the patient will not receive enteral nutrition for more than 5 to 7 days, the clinician may also want to supplement the PN solution with vitamin K1 (0.5 mg/kg SC once weekly).

    Virtually all sources indicate that B vitamins should be supplemented in patients receiving TPN. B vitamins are essential in the use of the dextrose, lipids, and amino acids delivered in the PN solution, and most patients ill enough to receive PN have B vitamin deficiencies. However, the actual amount of B vitamins required by critically ill animals and the amount added to PN solutions vary widely in the veterinary literature.

    The exact formulation and dose of supplemental B vitamins are also rarely mentioned. Original sources recommend that the B vitamin preparations include at least five to seven of the "important" B vitamin types (i.e., folic acid, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, B12) but do not specify a particular preparation or dose.2 A frequently published B vitamin supplementation recommendation is to add 1 ml of B complex vitamins per 1,000 kcal of energy supplied in the PN admixture; this amount can supply more than the minimum nutritional requirements of B vitamins for adult dogs and cats as determined by the National Research Council on the Nutritional Requirements of Dogs and Cats.15 However, those recommendations re­flect enteral nutrition requirements and may not be correct when nutrition is supplied parenterally.

    Our institution uses a vitamin B complex solution containing (per milliliter) 12.5 mg of thiamine hydrochloric acid, 12.5 mg of niacinamide, 2 mg of riboflavin, 5 mg of d-panthenol, and 0.2 ppm cobalt as vitamin B12. One milliliter of the solution per 1,000 kcal of TER is estimated to well exceed the dietary requirements of dogs and cats.

    Partial Parenteral Nutrition Formulation

    If three-in-one admixtures of partial parenteral nutrition (PPN) containing lipids, dextrose, and amino acids are being administered, the following guidelines apply16 (Tables 3 and 4).

    Step 1

    Calculate the TER as detailed in Steps 1 and 2 in the "Total Parenteral Nutrition Formulation" section.

    Step 2

    Partial daily energy requirement (PER) = 50% x TER

    Step 3: Determine the Calorie Sources for the Patient

    • It is recommended that a dog or cat weighing less than 22 lb (10 kg) receives 25% of PER as dextrose, 25% as amino acids, and 50% as lipids.
    • A dog weighing 22 to 55 lb (10 to 25 kg) can receive its energy requirements equally from dextrose, amino acids, and lipids (i.e., 33% of its energy requirements from dextrose, 33% from amino acid sources, and 33% from lipid sources).
    • A dog heavier than 55 lb (25 kg) should receive 50% of its energy requirements from dextrose, 25% from amino acid sources, and 25% from lipid sources.

    This variation in the composition of PPN solution is an attempt to keep the total volume consistent among patients of varying weights. However, patients weighing less than 6.6 lb (3 kg) will still receive a volume of fluid greater than their daily maintenance requirements to fulfill their daily energy requirements. In addition, it is interesting to note that this formulation of PPN uses amino acids to directly supply the patient's energy needs rather than to support muscle anabolism as with TPN. Patients receiving PPN should also receive enteral nutrition: the PPN solution should not be relied on to meet all nutritional requirements.

    Step 4: Determine the Volume of Nutrient Solutions Required


    5% (50 g/dl) Dextrose solution = 0.17 kcal/ml PER x % Calories as dextrose = ___ kcal/day dextrose ÷ 0.17 kcal/ml = ___ ml/day

    With the use of 5% dextrose rather than 50% dextrose, the resulting osmolarity of the PN solution will be much less than that of TPN and, therefore, make the solution safe to administer through a peripheral vein. (For a more complete discussion of osmolarity, see the companion article.)


    20% (200 g/L) Lipid emulsion = 2 kcal/ml PER x % Calories as lipid = ___ kcal/day lipids ÷ 2 kcal/ml = ___ ml/day

    Amino Acids

    8.5% (8.5 g/L) Amino acid solution = 0.34 kcal/ml PER x % Calories as amino acids = ___ kcal/day ÷ 0.34 kcal/ml = ___ ml/day

    An alternative method to reduce PPN osmolarity is to use a 3.5% amino acid solution instead of an 8.5% solution. These 3.5% solutions contain 3.5 g of protein equivalent in amino acids per deciliter and are of lower osmolarity than 8.5% amino acid solutions. Before PPN formulations using 3.5% amino acid solutions are used, other sources can be consulted.

    Step 5: Determine the Total Volume of PPN Solution Per Day

    (___ ml of dextrose + ___ ml of lipids + ___ ml of  amino acids) ÷ 24 hr = ___ ml/hr

    PPN is typically started immediately at the maintenance rate but can initially be given at half of the calculated rate for the first 6 to 12 hours and then increased to the full calculated rate.8 PPN solutions are much less likely to induce hyperglycemia and the refeeding syndrome than are TPN solutions, and thus less importance is placed on gradually introducing the PPN solution to the patient.

    Step 6: Add Vitamin Supplements

    If the patient will not receive enteral nutrition for more than 5 to 7 days, the clinician may want to supplement the patient with vitamin K (0.5 mg/kg SC once weekly).

    Most sources indicate that B vitamins should be supplemented in patients receiving PPN. However, this recommendation varies widely with each publication, and as already discussed with TPN formulations, the exact components of the B vitamin complex are not directly defined in any source. As with TPN, a typical B vitamin supplementation is to add 1 ml of B complex vitamins per 1,000 kcal of energy supplied in the PN admixture.15 Also, as with TPN, the assumption is made that vitamin requirements for PN are the same as those for enteral nutrition.

    Alternative Partial Parenteral Nutrition Sources

    An alternative to the three-in-one admixtures with lipids, dextrose, and amino acids is the use of PPN solutions with only amino acids and/or dextrose. Several solutions are available commercially. One formulation is a mixture of 3% amino acids, glycerol, and electrolytes and is available commercially or created by mixing 300 ml of 8.5% amino acid solution with 700 ml of lactated Ringer's solution plus 5% dextrose. This solution can be administered continuously for longer than 24 hours because it does not contain lipids, which deteriorate over time. The published dosage for this solution is 40 to 45 ml/kg/day.17 Downsides of this preparation are that it does not attempt to meet vitamin requirements in the patient and its osmolarity is higher than a three-in-one PPN admixture because it does not contain isosmolar lipids to dilute the hyperosmolar dextrose and amino acids. However, these PPN sources are advantageous in that the practitioner can either purchase the premixed solutions or easily prepare them using appropriate aseptic technique from supplies readily available.

    It should be remembered that when dextrose, amino acids, and lipids in PPN and TPN solutions are metabolized, free water is produced. After metabolism, the volume of water delivered to a patient is roughly equivalent to the volume of solution administered. PPN calculations (especially for three-in-one admixtures) may require the use of a larger volume of solution than is practical or safe to administer to a given patient. Conversely, larger patients may require additional electrolyte fluid solutions to completely meet their daily fluid requirements, especially if the patient needs a large volume of fluids. Also, if electrolytes are not added to PPN solutions or the patient has many electrolyte abnormalities, the patient will require concurrent administration of electrolyte-containing fluids through another intravenous catheter.

    Patient Monitoring

    Careful monitoring of patients receiving PN is important to identify and rectify metabolic abnormalities that may develop.2,5,6,8 Recommendations vary, but all sources agree that vital signs (i.e., temperature, pulse and respiratory rates, patient attitude) should be serially monitored every 4 to 6 hours for the first 2 to 3 days and at a decreasing frequency thereafter. Body weight should be measured every 12 to 24 hours.

    Blood and urine glucose should be evaluated at least every 12 hours for the first 2 to 3 days for evidence of hyperglycemic complications. All sources agree that if the patient's blood glucose is persistently elevated over 200 mg/dl, steps should be taken to combat hyperglycemia.2,6,8 Some clinicians might be more aggressive by addressing hyperglycemia at much lower blood glucose concentrations.

    Steps to address hyperglycemia include initially decreasing the PN fluid administration rate and potentially administering regular insulin to bring the blood glucose concentration within the normal range.2,8 Insulin can be administered by intermittent intramuscular or subcutaneous injections or by a constant-rate infusion of 1 to 2 U/kg/24 hr for dogs or at a starting dose of 1 U/cat/24 hr.8 Regular insulin is preferred in these situations because of its short duration of action and the ease with which the dose can be altered. A third and perhaps less cost-effective option to combat persistent hyperglycemia is reformulation of the PN solution with a smaller percentage of dextrose and a greater percentage of lipids to provide energy requirements. Retrospective studies18-21 in veterinary medicine reveal that although hyperglycemia is common and usually transient in most cases, many animals that become hyperglycemic require at least temporary insulin therapy.

    Some authors feel that the blood glucose monitoring regimen should be very strict to avoid any chance of PN-induced hyperglycemia, especially for the first days of PN supplementation8 (Figure 1). According to Figure 1 , if the blood glucose concentration at subsequent rechecks remains greater than 200 to 250 mg/dl, the PN infusion rate should be decreased to the highest rate that maintains the blood glucose concentration below 250 mg/dl. If the blood glucose concentration rises above 300 mg/dl, the PN infusion rate should be decreased and the patient may need insulin therapy.

    Serum electrolytes and renal parameters are also important to monitor at least every 24 hours for the first 2 to 3 days of PN administration and, if no complications occur, less regularly thereafter. Evidence of hypokalemia, hypophosphatemia, or other changes consistent with the refeeding syndrome can be handled as described in the Refeeding Syndrome section. Azotemia, especially increases in blood urea nitrogen concentration, may be due to excessive protein supplementation and can be addressed by decreasing the amino acid content of the PN admixture.

    Some authors feel that packed cell volume and total protein parameters should be serially monitored in patients receiving PN.6 Others feel that a patient's blood should be checked at least every 12 to 24 hours for evidence of lipemia via visual inspection of the serum and/or examination of serial triglyceride measurements for the first 2 to 3 days and then with decreasing frequency thereafter.2 Lipemia might indicate excessive administration of lipid sources and can be addressed by decreasing the lipid proportion of the feeding admixture.

    It is clear from all sources that animals receiving PN should be closely and serially monitored to identify and correct metabolic abnormalities. Similarly, as dictated by common sense, a patient should slowly be weaned off PN over the course of at least 12 to 24 hours to decrease rebound hypoglycemia or other electrolyte changes that could be induced by abrupt cessation of nutritional ­support.8

    Other parameters that are typically monitored in patients receiving PN at the University of Missouri in­clude central venous pressure (CVP) measurements, especially in animals receiving additional isotonic crystalloids or electrolyte solutions with their PN. This is accomplished by using a multilumen central venous catheter in the patient: one lumen is dedicated to PN administration, and the other can be used for CVP monitoring. Serial CVP measurements are used to prevent volume overload while patients receive nutrition. Checking the patient's serum osmolarity every 24 hours also ensures that the PN solution is not causing the patient's serum to become hyperosmolar. Increases in CVP or serum osmolarity can be addressed by decreasing the rate of PN administration or the amount of dextrose administered in the solutions. In addition, the catheter site should be visually inspected at least every 12 hours. Extravasation of PN solutions leading to local tissue inflammation and necrosis is a potential complication of PN. If extravasation is detected, the PN catheter must be removed and replaced in another location. Ice packs and hydrotherapy can be administered to the affected region.

    Disadvantages of Parenteral Nutrition

    The drawbacks of PN can be divided into four categories:

    • Infection
    • Mechanical complications
    • Cost
    • Metabolic complications

    Infection occurs secondary to contamination and growth of bacteria and fungi in a PN bag, nosocomial bacterial or fungal contamination during administration of PN, or bacterial translocation from the patient's own body (specifically the gastrointestinal tract or skin at the catheter site). Contamination of the PN bag during compounding and nosocomial infection introduced during administration of PN can be controlled by careful preparation of PN and aseptic handling of the intravenous tubing as discussed in the companion article (also,see box).

    Mechanical complications include intravenous line breakage or kinking, patient destruction of intravenous lines or catheters, clogging of intravenous lines, and thrombophlebitis. Careful monitoring of patients can help minimize these occurrences, and the use of polypropylene catheters has been shown to decrease the incidence of thrombo­phlebitis.22-24 Metabolic complications such as biochemical or electrolyte abnormalities may be induced by PN administration and can include hyperglycemia, hypo­phos­phatemia, and hypokalemia.

    In a retrospective study21 of PPN administration in dogs and cats, metabolic, mechanical, and septic complications were reported. In this study, hyperglycemia (blood [serum] glucose concentration: >120 mg/dl) was the most frequent metabolic complication. Other noted complications included hyperbilirubinemia, lipemia, and azotemia. No patients required insulin therapy, and hyper­glycemia improved within 1 to 3 days. The likelihood of metabolic complications was not found to be significantly different between cats and dogs. Mechanical complications were more common in dogs (26% of dogs versus 9% of cats had complications) and included occlusion of catheters, line breakage, disconnections, and thrombophlebitis. There was only a 3% reported rate of septic complications in both species.

    In two retrospective studies18,19 of TPN use in both dogs and cats, mechanical complications were frequent. Forty-six percent of the mixed canine and feline population described by Lippert et al18 had mechanical complications compared with 21% of the feline-only population described by Pyle et al.19 Hyperglycemia was another common complication in 75% of all cats18 and 47% of nondiabetic cats19 (>140 mg/dl18 and >134 mg/dl,19 respectively). Similarly, 46% of all dogs18 had high blood glucose values (>140 mg/dl) while receiving TPN. Other metabolic derangements detected in animals receiving TPN were hypo- and hypernatremia, hypo- and hyper­kalemia, hypo- and hypercalcemia, and hypo- and hyperphosphatemia. However, these abnormalities were much less common than hyperglycemia-at the most, 10% of Lippert et al's18 canine and feline populations and 34% of Pyle et al's19 feline-only population. Lipemia was noted in 46% of cats and dogs18 and 24% of cats.19

    Clinical signs attributable to metabolic complications were rare in both studies,18,19 although some patients required insulin administration for persistent (i.e., longer than 3 days) hyperglycemia. Lippert et al18 reported that 36% of hyperglycemic dogs and 67% of hyperglycemic cats required insulin therapy. Although Pyle et al19 did not report a percentage of cats requiring insulin, most hyperglycemic cats required insulin therapy. There was an overall low rate of septic complications, with Lippert et al18 showing no septic complications in either cats or dogs and Pyle et al19 finding TPN-associated sepsis in only five of 84 cats.

    PN is not an inexpensive feeding modality. PN components are fairly inexpensive individually, but when they are combined into admixtures, the cost of each component is additive. In addition, when PN is formulated by a pharmacy, there is a dispensing and formulation charge for costs associated with the use of the laminar flow hood, the materials (e.g., syringes, needles, tubing) needed to compound the solution, and the expertise and time of the pharmacist. The specialized ethylene vinyl acetate PN bag is also a substantial cost. At the University of Missouri-Columbia Veterinary Medical Teaching Hospital, the bag itself represents 33% of the daily cost of PN. When all factors are taken into account, the cost of PN can be $100/day or more for the client and, therefore, may be cost prohibitive or limit the duration that PN can be provided to a patient.

    Refeeding Syndrome

    Refeeding syndrome is a complication of nutritional supplementation that, although it can occur in animals, is more commonly reported in humans. It is a syndrome of severe hypophosphatemia, hypokalemia, hypomagnesemia, and other electrolyte derangements that can be induced in an anorectic, malnourished patient by providing nutrient supplementation25,26 (oral, enteric, or parenteral). Patients typically have hyperglycemia as well. Hyperglycemia and concurrent glucosuria can lead to osmotic diuresis, resulting in sodium and water loss. However, in other cases, especially in patients fed mainly carbohydrate sources, feeding leads to reduced sodium and water excretion and, in some cases, can lead to increases in extracellular fluid volume and eventually peripheral edema.26

    Hypophosphatemia is the most significant feature of refeeding syndrome in humans.25-27 It occurs when there has been starvation-induced loss of lean muscle mass, minerals, and water. The patient's whole body phosphorus is depleted in this stage, although blood work results typically do not reflect this. When nutrition is provided to such a patient, the presence of carbohydrates causes the release of insulin, which induces an intracellular shift of phosphorus, causing clinically mea­surable serum hypophosphatemia. As the patient is fed, conversion from catabolism to anabolism occurs, and the body begins to create cell membranes, nucleic acids, ATP, and 2,3-diphosphoglycerate (2,3-DPG), all of which require phosphorus. This demand for phosphorus magnifies the preexisting hypophosphatemia.

    Refeeding syndrome is clinically recognized and typically occurs about 3 days after initiation of nutritional intervention.25,26 Hypophosphatemia leads to decreased cardiac contractility through an undefined mechanism as well as decreased leukocyte function. A wide spectrum of neuromuscular dysfunction can occur, ranging from muscular paralysis to cranial nerve deficits and ventilatory dysfunction. These neuromuscular changes may be due to hypoxic cellular injury resulting from decreased oxygen delivery to tissues caused by decreased 2,3-DPG in erythrocytes. Hypoxia may also result from decreased erythrocyte delivery to tissues through capillary beds as erythrocyte membranes lose their pliability when the patient is hypophosphatemic. Severe hypo­phosphatemia may also lead to hemolytic anemia.

    Hypomagnesemia and hypokalemia can cause clinical signs similar to those of hypophosphatemia, including cardiac arrhythmias, weakness, seizures, and ataxia.26,27 The functions of magnesium are not completely characterized but seem to parallel those of phosphorus and potassium. Both hypokalemia and hypomagnesemia occur in the refeeding syndrome due mainly to the increase in insulin and accompanying shifting of potassium, magnesium, and phosphorus into the cells.25-27

    Patients with prolonged anorexia or starvation should be gradually introduced to parenteral and enteral feeding over the course of 2 to 3 days to acclimate the body to the infusion of calories. This gradual introduction to calories minimizes the chance of inducing the refeeding syndrome. The patient should be carefully monitored, including serial electrolyte and blood glucose monitoring, during the first days of supplementation. Not every patient undergoes this syndrome, but every patient is at risk.

    Although the refeeding syndrome is recognized and reported in humans, few veterinary publications have explicitly addressed the syndrome. As noted previously, both hypo- and hyperphosphatemia were reported in animals administered TPN and PPN.18,19 These studies had a slightly greater prevalence of hyperphosphatemic than hypophosphatemic complications, although the total numbers were very small in both studies. These studies were retrospective and did not directly address reasons for these electrolyte abnormalities. A single veterinary case study28 describing the refeeding syndrome in a chronically anorectic cat was characterized by severe hypokalemia and normal phosphorus concentrations.

    If persistent hypophosphatemia results from PN ad­ministration, the patient can receive intravenous phosphorus supplementation. The recommended phosphorus dosage is 0.003 mmol/kg/hr IV for the first 24 hours or 0.03 mmol/kg/hr for a total of 6 hours.27 Hypokalemia is best treated using oral supplementation, although this is typically impossible in animals receiving PN. However, potassium can be added to the patient's intravenous fluids29 (Table 5).

    Magnesium should be administered to patients with total serum magnesium concentrations below 1.2 mg/dl (normal: 1.7 to 2.4 mg/dl).30 Magnesium supplementation should be administered as a 20% dilution by combining magnesium sulfate or magnesium chloride with 50% dextrose. This solution can be given as a constant-rate infusion of 0.75 to 1 mEq/kg/day for the first day, followed by 0.3 to 0.5 mEq/kg/day of the diluted magnesium solution for an additional 3 to 5 days. As an alternative in certain patients, oral supplementation of magnesium (magnesium oxide or hydroxide supplements) may be given at a dose of 1 to 2 mEq/kg/day.


    Although the effectiveness of PN has not been proven in animals, human studies have shown that using PN in appropriately selected cases can improve clinical outcomes, reduce hospitalization time, and even reduce the overall cost of patient care.31 Parenteral feeding through TPN and PPN administration provides nutrition to improve clinical outcome but also has a substantive cost and inherent complications. Careful monitoring of patients while they are receiving PN can help identify and correct these complications. It is important to have a dedicated nursing staff that closely monitors patients receiving PN to avoid mechanical complications. Frequent blood draws and biochemical analyses over the first 2 to 3 days of PN administration can help identify metabolic complications. Careful compounding and sterility when handling PN can reduce infectious complications. Overall, PN is a viable option for patients that cannot receive food enterally.

    *A companion article on uses, indications, and compounding begins here.

    See the box on How to Get Started .

    Downloadable PDF

    aDr. Thomovsky is conducting research funded by the Waltham Foundation.
    bDr. Reniker is now affiliated with First Regional Animal Hospital, Chandler, Arizona.

    1. Rombeau JL, Rolandelli RH: Clinical Nutrition: Parenteral Nutrition. Philadelphia, WB Saunders, 2001.

    2. Remillard RL, Thatcher CD: Parenteral nutritional support in the small animal patient. Vet Clin North Am Small Anim Pract 19:1287-1306, 1989.

    3. Lippert AC, Armstrong PJ: Parenteral nutritional support, in Kirk RW, Bonagura JD (eds): Current Veterinary Therapy Small Animal Practice X. Philadelphia, WB Saunders, 1989, pp 25-30.

    4. Bartges JW: Identifying and feeding patients that require nutritional support. Vet Med 96:60-73, 2001.

    5. Armstrong PJ, Lippert AC: Enteral and parenteral nutritional support. Semin Vet Med Surg (Small Anim) 3:216-226, 1988.

    6. Kelly NC, Wills JM: BSAVA Manual of Companion Animal Nutrition & Feeding. Ames, Iowa State University Press, 1996.

    7. O'Toole E, Miller CW, Wilson BA, et al: Comparison of the standard predictive equation for calculation of resting energy expenditure with indirect calorimetry in hospitalized and healthy dogs. JAVMA 225:58-64, 2004.

    8. Macintire DK, Drobatz KJ, Haskins SC, et al: Manual of Small Animal Emergency and Critical Care Medicine. Philadelphia, Lippincott Williams & Wilkins, 2005.

    9. Patino JF, de Pimiento SE, Vergara A, et al: Hypocaloric support in the critically ill. World J Surg 23:553-559, 1999.

    10. Bistrian BR, Babineau T: Optimal protein intake in critical illness? Crit Care Med 26:1476-1477, 1998.

    11. Mauldin GE, Reynolds AJ, Mauldin NG, et al: Nitrogen balance in clinically normal dogs receiving parenteral nutrition solutions. Am J Vet Res 62:912-920, 2001.

    12. Dudrick SJ, Wilmore DW, Vars HM, et al: Long-term total parenteral nutrition with growth, development, and nitrogen balance. Surgery 64:134-142, 1968.

    13. Humbert B, Bleis P, Martin L, et al: Effects of dietary protein restriction and amino acids deficiency on protein metabolism in dogs. J Anim Physiol Anim Nutr 85:255-262, 2001.

    14. Riond JL, Stiefel M, Wenk C, et al: Nutrition studies on protein and energy in domestic cats. J Anim Physiol Anim Nutr 87:221-228, 2003.

    15. Remillard RL, Armstrong PJ, Davenport DJ: Assisted feeding in hospitalized patients: Enteral and parenteral nutrition, in Hand MS, Thatcher CD, Remillard RL, et al (eds): Small Animal Clinical Nutrition, ed 4. Marceline, MO, Walsworth Publishing, 2000, pp 351-400.

    16. Zsombor-Murray E, Freeman LM: Peripheral parenteral nutrition. Compend Contin Educ Pract Vet 21:512-523, 1999.

    17. Plunkett SJ: Emergency Procedures for the Small Animal Veterinarian, ed 2. London, WB Saunders, 2002.

    18. Lippert AC, Fulton RB, Parr AM: A retrospective study of the use of total parenteral nutrition in dogs and cats. J Vet Intern Med 7:52-64, 1993.

    19. Pyle SC, Marks SL, Kass PH: Evaluation of complications and prognostic factors associated with administration of total parenteral nutrition in cats: 75 cases (1994-2001). JAVMA 225:242-250, 2004.

    20. Lippert AC, Faulkner JE, Evans AT, et al: Total parenteral nutrition in clinically normal cats. JAVMA 194:669-676, 1989.

    21. Chan DL, Freeman LM, Labato MA, et al: Retrospective evaluation of partial parenteral nutrition in dogs and cats. J Vet Intern Med 16:440-445, 2002.

    22. Solomon DD, Arnold WL, Martin ND, Lentz DJ: An in vivo method for the evaluation of catheter thrombogenicity. J Biomed Mater Res 21:43-57, 1987.

    23. Pottecher T, Forrler M, Picardat P, et al: Thrombogenicity of central venous catheters: Prospective study of polyethylene, silicone and polyurethane catheters with phlebography or post-mortem examination. Eur J Anaesthesiol 1:361-365, 1984.

    24. Linder LE, Curelaru I, Gustavsson B, et al: Material thrombogenicity in central venous catheterization: A comparison between soft, antebrachial catheters of silicone elastomer and polyurethane. JPEN J Parenter Enteral Nutr 8:399-406, 1984.

    25. Marinella M: The refeeding syndrome and hypophosphatemia. Nutr Rev 61:320-323, 2003.

    26. Solomon SM, Kirby DF: The refeeding syndrome: A review. JPEN J Parenter Enteral Nutr 14:90-97, 1990.

    27. Miller CC, Bartges JW: Refeeding syndrome, in Bonagura JD (ed): Kirk's Current Veterinary Therapy XIII. Philadelphia, WB Saunders, 2000, pp 87-89.

    28. Tsai Y-C, Jeng T-S, Jeng C-R, et al: Case report: Refeeding syndrome in a cat. Taiwan Vet J 29:66-70, 2003.

    29. Rubin SI: Management of fluid and electrolyte disorders in uremia, in Bonagura JD (ed): Kirk's Current Veterinary Therapy XII. Philadelphia, WB Saunders, 1995, pp 951-955.

    30. Dhupa N: Magnesium therapy, in Bonagura JD (ed): Kirk's Current Veterinary Therapy XII. Philadelphia, WB Saunders, 1995, pp 132-133.

    31. The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group: Perioperative total parenteral nutrition in surgical patients. N Engl J Med 325:525-532, 1991.

    References »

    NEXT: Parenteral Nutrition: Uses, Indications, and Compounding

    CETEST This course is approved for 2.0 CE credits

    Start Test


    Did you know... Osteoarthritis affects approximately 20% of dogs older than 1 year.Read More

    These Care Guides are written to help your clients understand common conditions. They are formatted to print and give to your clients for their information.

    Stay on top of all our latest content — sign up for the Vetlearn newsletters.
    • More